Associations of habitual glucosamine use with SARS-CoV-2 infection and hospital admission and death with COVID-19:

Evidence from a large population based cohort study

Meijun Meng, MD^{+1,2}; Yanjun Wu, MD^{+1,2}; Ruijie Zeng, MD^{+1,3}; Dongling Luo, MD⁺⁴; Rui Jiang, BS^{1,5}; Huihuan Wu, MD^{1,5}; Zewei Zhuo, MS¹; Qi Yang, BS¹; Jingwei Li, MD^{1,5}; Felix W Leung, MD^{+6,7}; Qian Chen, PhD^{+8,9,10}; Weihong Sha, MD, PhD^{+1,2,3,5}; Hao Chen, MD, PhD^{+1,2,3,5}

¹Department of Gastroenterology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China

²The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China

³Shantou University Medical College, Shantou 515000, Guangdong, China

⁴Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China

⁵School of Medicine, South China University of Technology, Guangzhou 510006, China

⁶David Geffen School of Medicine, University of California Los Angeles, Los Angeles 90032, California, USA

⁷Sepulveda Ambulatory Care Center, Veterans Affairs Greater Los Angeles Healthcare System, North Hills 16111, California, USA

⁸Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China

⁹Guangdong Provincial Key Laboratory of Arrhythmia and Electrophysiology, Guangzhou 510120, China

¹⁰Guangdong Provincial Key Laboratory of Food, Nutrition and Health, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China

*Correspondence:

Prof. Felix W Leung, David Geffen School of Medicine, University of California Los Angeles, Los Angeles 90032, California, USA; E-mail: Felix.Leung@va.gov

Dr. Qian Chen, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China; Email: chenq353@mail.sysu.edu.cn

Prof. Weihong Sha, Department of Gastroenterology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China; E-mail: shaweihong@gdph.org.cn

Prof. Hao Chen, Department of Gastroenterology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China; E-mail: chenhao@gdph.org.cn

†: These authors contributed equally to this work

Abstract

Objectives

To assess the association of habitual glucosamine use with coronavirus 2 (SARS-CoV-2) infection, hospital admission, or mortality with Corona Virus Disease-19 (COVID-19) in a large population based cohort.

Design

Population based, prospective cohort study.

Setting

UK Biobank.

Participants

Participants with complete information on habitual glucosamine use and SARS-CoV-2 infection or COVID-19-related outcomes were included. These participants were registered from 2006 to 2010, followed up until 2022 and participated in SARS-CoV-2 tests between 2020 and 2022.

Main outcome measures

SARS-CoV-2 infection, COVID-19 hospital admission, and COVID-19 mortality.

Results

At baseline, 20,118 (15.9%) of the 126,518 participants reported as habitual glucosamine users. During the median follow-up 12.16 years, there were 53,682 cases of SARS-CoV-2 infection, 2,120 cases of COVID-19 hospital admission and 548 cases of COVID-19 mortality. The multivariate adjusted hazard ratios of habitual glucosamine users to non-users were 1.02 (95% confidence interval [CI] 0.99 to 1.05) for SARS-CoV-2 infection, 0.73 (95% CI 0.63 to 0.85) for COVID-19 hospital admission, and 0.74 (95% CI 0.56 to 0.98) for COVID-19 mortality. The Cox proportional hazard analysis after propensity-score matching yielded consistent results.

Conclusions

Habitual glucosamine use seems to be associated with a lower risk of hospital admission and mortality with COVID-19, but not the risk of SARS-CoV-2 infection.

1. Introduction

The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has contributed to a substantial number of severe cases and mortality worldwide¹. COVID-19 can trigger cytokine storms in pulmonary tissues, contributing to detrimental pathological features and lethal complications^{2,3}. It was estimated that the global in-hospital mortality with coronavirus disease was 15%, and over 18 million people had died due to the COVID-19 pandemic^{1,4}.

Glucosamine is an amino monosaccharide that naturally exists in connective tissues, and its oral supplements can be used for the management of osteoarthritis ⁵. It has been estimated that 20% of the adults in the United States use glucosamine ⁶. In the United Kingdom, glucosamine is available as a prescription-only medicine for symptomatic relief. Glucosamine and its related products are demonstrated preclinically to mediate and alleviate the process of inflammation by modulating inflammatory mediators such as nitric oxide and reactive oxygen species ⁷⁻¹¹. Recent studies have indicated that habitual glucosamine use decreases the risk of cardiovascular events, type 2 diabetes, lung cancer, and all-cause mortality ¹²⁻¹⁴.

To date, the associations between habitual glucosamine use and COVID-19 remain unexplored. Given the anti-inflammatory effect and extensive use of glucosamine and the high prevalence of COVID-19 worldwide, it is critical to evaluate their linkages. Herein, by leveraging the updated and population-based cohort data from the UK Biobank, we aim to evaluate the association between habitual glucosamine use and the risks of SARS-CoV-2 infection and hospital admission and death with COVID-19.

2. Methods

2.1 Study setting and participants

The UK Biobank was a large prospective study involving 502,413 participants recruited between 2006 and 2010. Participants between the ages of 37 and 73 were invited to one of 22 centers for a baseline assessment and where they completed a detailed touchscreen questionnaires and face-to-face interviews, provided biological samples, and also had a series of physical measurements. Written informed consent was acquired from each participant, and ethical approval was obtained from the North West Multi-Center Research Ethics Committee (approval number: 11/NW/0382, 16/NW/0274, and 21/NW/0157). The current study has been approved under the UK Biobank project 83339.

Data from 502,413 participants were available for our study. We excluded participants with incomplete data on glucosamine-covariate at baseline (n=194,385), incomplete data on the SARS-CoV-2 infection or COVID-19 outcomes (n=152,603) and those with the date of death earlier than January 31, 2020 (n=28,907). In total, our analysis included 126,518 participants (**Figure 1**; **Supplementary Table S2**).

2.2 Ascertainment of exposure

The touch screen food frequency questionnaire contained a series of questions: "Do you regularly take any of the following supplements?" Participants could select their answer from a list of supplements, which included glucosamine use (https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=6179;id=10007;id=20003). From this information, we defined habitual glucosamine usage as 0=no and 1=yes. We only use the

assessment of glucosamine supplement use at baseline to perform analyses.

2.3 Ascertainment of COVID-19

In this study, the outcomes of SARS-CoV-2 infection (n=53,682), COVID-19 hospital admission (n=2,120) and COVID-19 mortality (n=548) would be focus on. The criteria of SARS-CoV-2 infection was defined as participants with a positive SARS-CoV-2 test and the criteria of COVID-19 hospital admission was defined as ICD-10 code for confirmed COVID-19 (U07.1) or probable COVID-19 (U07.2) in hospital records (excluded those who died from the virus without being hospitalized (n=160)). We defined the fatal outcome as COVID-19 mortality with COVID-19 (ICD-10 U07.1 and U07.2) as the cause of death according to data from the death registers.

2.4 Ascertainment of covariates

We used the baseline questionnaire to assess several factors: sociodemographic characteristics (age, sex, ethnicity), socioeconomic status (Townsend Deprivation Index, educational attainment, and household income), lifestyle factors (smoking status, alcohol consumption, body mass index (BMI), dietary intake (vegetables, fruit), comorbidities (hypertension, type 2 diabetes, hypercholesterolemia and arthritis), supplement or co-medication use (antihypertensive drugs, hypolipidemic drugs, insulin, non-aspirin non-steroidal anti-inflammatory drugs [NSAID] and aspirin), vitamin supplementation (vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, multivitamin, or folic acid), and mineral and other dietary supplementation (calcium, iron, zinc, or selenium). These factors were regarded as covariates need to be adjusted in our study, using the directed acyclic graph (DAG) based on existed literature and expert study. (Supplementary Figure 1)

The Townsend Deprivation Index, used as an indicator of socioeconomic status, is derived from the residential postcode and is provided directly from the UK Biobank. BMI was calculated as the weight in kilograms (kg) divided by the square of the height in meters (m²). Information on comorbidities (hypertension, type 2 diabetes, hypercholesterolemia and arthritis) was collected by self-report at baseline. Prevalent hypertension was defined as a self-reported history of hypertension, the use of antihypertensive drugs, a systolic blood pressure of 140 millimeters of mercury (mmHg) or higher, or a diastolic blood pressure of 90 mmHg or higher. Arthritis was defined by ICD-10 codes (M00-M03, M05-M14).

2.5 Statistical analyses

Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) of three different outcomes (SARS-CoV-2 infection, COVID-19 hospital admission, and COVID-19 mortality) according to glucosamine use (yes or no) after confirming whether the assumption of proportional hazards in the Cox regression models was met. It was worth mentioning that the assumption of proportional hazards was fulfilled for main exposure in all outcomes by using Schoenfeld residuals test, which meant the reliability of the Cox proportional hazards model results was high. Three sets of models were used. The non-adjusted model would be set as Model I. Model II was adjusted for age (years) and sex (male or female). The multivariable model (model III) was adjusted for all covariates, including age (years), sex, the Townsend Deprivation Index, ethnicity (white European and others), household income (<£18□000 (\$23□500; €21□000), £18□000-£30□999, £31□000-£51□999, £52□000-£100□000, or >£100□000 and "do not know" or missing), educational attainment (college or university degree, non-college or university degree), BMI, fruit consumption (<2.0,

2.0-3.9, or ≥3.9 servings/day), vegetable consumption (<2.0, 2.0-3.9, or ≥3.9 servings/day), smoking status (never, former, or current), alcohol consumption (never, special occasions only, 1-3 times/months, 1-2 times/week, 3-4 times/week, or ≥5 times/week), type II diabetes (yes or no), hypertension (yes or no), hypertension (yes or no), arthritis (yes or no), antihypertensive drugs (yes or no), hypolipidemic drugs (yes or no), insulin treatment (yes or no), non-aspirin NSAID drugs use (yes or no), aspirin use (yes or no), vitamin supplementation (yes or no), and mineral and other dietary supplementation (yes or no). Person-years were calculated from the date of baseline recruitment to the date of outcome diagnoses, last follow-up (January 2022 for SARS-CoV-2 infection or COVID-19-related outcomes), whichever came first.

We performed a stratified analysis to assess potential modification effects by the following factors: sex (female or male), age (<60 or ≥60), body mass index (<27 or ≥27), Townsend Deprivation Index (<mean or \ge mean), household income (<52000 or ≥52000),smoking (never, former, or current), alcohol consumption (never, <3 times/week or ≥3 times/week), educational attainment (college or university degree, non-college or university degree), antihypertensive drugs (yes or no), non-aspirin NSAID drugs use(yes or no), type II diabetes (yes or no), hypertension (yes or no), hypercholesterolemia (yes or no), arthritis (yes or no). Simultaneously, the multiplicative interaction between glucosamine use and each covariate on study outcomes were tested, which expressed as P for interaction.

Furthermore, we carried out propensity scores matching for glucosamine exposure as an addition to adjust covariates. We matched glucosamine users to non-users at 1:1 ratio using a greedy nearest neighbor method with the MATCHT package in R. The overall quality of the

matched sample was assessed by comparing the standardized mean differences (SMD) of all covariates. Among them, the unbalanced covariates between groups (SMD ≥ 0.1) were further adjusted in Cox proportional hazards models to recalculate HRs and 95% Cls. Additionally, the assumption of proportional hazards in the Cox regression models was met here.

We performed all analyses using R software (version 4.2.0, https://www.r-project.org/) in RStudio. We considered a *P* value less than 0.05 (two-sided) to be statistically significant.

2.6 Patient and public involvement

No patients were involved in setting the research question or the outcome measures, or in developing plans for design or implementation of the study. No patients were asked to advise on interpretation or writing up of results.

3. Results

3.1 Population characteristics

Table 1 shows the baseline characteristics of included participants by glucosamine supplementation usage. The median follow-up was 12.16 (interquartile range [IQR] 11.49-12.82) years. Overall, the mean age of included participants was 55.06 years and 41.2% were male. Among them, 20,118 (15.9%) were glucosamine users, and 106,400 (84%) were glucosamine non-users. Compared with non-users, participants who use glucosamine supplementation were more likely to be female, Caucasians, never smokers, had lower Deprivation index, had medium household income (31,000-51,999£), had three or four times a week alcohol consumption, had college or university degree, had 2-3.9 tablespoons of fresh

fruits and raw vegetables per day, and had a lower prevalence of included comorbidities that involved hypertension, type 2 diabetes, hypercholesterolemia and arthritis. Simultaneously, the participants using glucosamine supplementation were also prone to taking vitamin, mineral, and other dietary supplementation, but did not tend to take medicines like antihypertensive drugs, hypolipidemic, insulin, aspirin and non-aspirin NSAIDs.

3.2 Glucosamine usage and outcomes

The associations for habitual glucosamine use with the risk of SARS-CoV-2 infection, COVID-19 hospital admission, and COVID-19 mortality after Cox proportional hazard analysis were shown in **Table 2**. Within the year recorded by the UK Biobank, we have collected a total of 126,518 participants related to outcome events. Among of them, there were 53,682 participants with all SARS-CoV-2 infection, 2,120 participants with COVID-19 hospital admission, and 548 participants with COVID-19 mortality. In the hazard ratios without adjustment models analysis, we discovered significant inverse associations between glucosamine users and the risk of COVID-19 hospital admission and mortality (all P<0.050). but significant positive association between glucosamine users and risk of SARS-CoV-2 infection (P<0.050). In addition, in the age and sex-adjusted models, we found inverse correlations that the adjusted hazard ratios associated with glucosamine users were 0.97 (95% CI 0.95 to 1.00; *P*=0.020) for SARS-CoV-2 infection; 0.67 (95% CI 0.58 to 0.76; *P*<0.001) for COVID-19 hospital admission; 0.61(95% CI 0.47 to 0.78; P<0.001) for COVID-19 mortality. Moreover, in the fully adjusted models, including age, sex, ethnicity, deprivation index, household income, BMI, alcohol consumption, smoking status, education, fresh fruit ingestion, raw vegetable ingestion, supplement or co-medication use and history of comorbidities, the

adjusted hazard ratios associated with glucosamine users were 0.73 (95% CI 0.63 to 0.85; P<0.001) for COVID-19 hospital admission and 0.74 (95% CI 0.56 to 0.98; P=0.040) for COVID-19 mortality, which were inverse correlations significantly. However, according to our analysis, there was no significant positive correlation between glucosamine users and risk of SARS-CoV-2 infection (HR 1.02; 95% CI 0.99 to 1.05; P=0.120).

Supplementary table 1 showed the demographic and clinical characteristics of participants after propensity score-matching (PSM). It listed all the covariates' standardized mean differences (SMD) were lower than 0.1, which meant well equilibrium and the low difference between groups of our study. Then, the Cox proportional hazard analysis after 1:1 ratio matching indicated consistent results for the outcomes. The hazard ratios associated with glucosamine users were 1.02 (95% CI 0.99 to 1.05; *P*=0.150) for SARS-CoV-2 infection; 0.70 (95% CI 0.60 to 0.82; *P*<0.001) for COVID-19 hospital admission; 0.72 (95% CI 0.53 to 0.97; *P*=0.030) for COVID-19 mortality (**supplementary table 3**).

3.3 Interaction and subgroup analyses

We performed subgroup analyses according to potential risk factors (**Figure 2**). A significant multiplicative interaction was observed between glucosamine usage and age on SARS-CoV-2 infection (*P* for interaction=0.001). Meanwhile, the interaction between glucosamine usage and BMI on SARS-CoV-2 infection was also significant (*P* for interaction=0.003). Additionally, we discovered the associations between glucosamine users and the risk of COVID-19 hospital admission outcome had stronger significant multiplicative interactions for alcohol consumption (*P* for interaction=0.010) and educational status (*P* for interaction=0.045). For example, as for COVID-19 hospital admission outcome, the hazard ratios for alcohol

consumption at least three times a week was 0.64 (95% CI 0.50 to 0.81), and was 0.68 (95% CI 0.56 to 0.81) for individuals without a college or university degree. Furthermore, the association between glucosamine users and these COVID-19 hospital admission outcome was stronger among alcohol consumption at least three times a week than among alcohol consumption less than three times per week or never. Whereas, the associations between glucosamine users and the risk of COVID-19 hospital admission outcome were not modified by other risk factors, including age, BMI, deprivation index, sex, household income, smoking status, antihypertensive drug use, non-aspirin NSAID use, hypercholestolemia, type 2 diabetes, hypertension, and arthritis. No significant multiplicative interaction was found between glucosamine users and all selected risk factors on fatal COVID-19 outcome (all *P* for interaction >0.050).

4. Discussion

In this large population-based cohort study, habitual use of glucosamine is associated with a 30% decreased risk of hospital admission and a 28% reduced risk of death among patients with COVID-19, but not the risk of infection. The associations for COVID-19 hospital admission and mortality are independent of age, gender, body mass index, deprivation index, household income, smoking, education, several medications, hypertension, diabetes, hypercholesterolemia, and arthritis.

4.1 Comparison with other studies

To our knowledge, none of the previous literature has evaluated the effects of habitual glucosamine on COVID-19. Although habitual glucosamine use has been identified to reduce

the risk of lung cancer, type 2 diabetes, cardiovascular diseases, and all-cause mortality by several observational studies¹²⁻¹⁷, its association with COVID-19 remains unknown. In addition, several studies on other dietary supplements, including vitamin C¹⁸, vitamin D¹⁹, and folic acid²⁰, did not identify any significantly reduced risks for the COVID-19-related outcomes under their use.

As the first attempt on this field, our study might have critical impacts on future research and clinical practice. In spite of the controversial evidence on the treatment of osteoarthritis by glucosamine ²¹, its supplementation could have additional benefits in improving other outcomes of the users. The reduced risks of hospital admission and fatal COVID-19 emphasize the potential benefits of glucosamine.

4.2 Biological plausibility

Several proposed mechanisms could account for the observed protective effect of glucosamine and COVID-19-related outcomes. The activation of immune cells, generation of cytokines and chemokines, as well as the positive pro-inflammatory feedback loops are involved in the inflammatory responses to SARS-CoV-2 ²²⁻²⁴. In consequence, controlling the inflammatory response is important in improving the hospital admission of COVID-19. Administration of glucosamine in mice decreases the production of inflammatory cytokines and alleviates systemic inflammation²⁵. Glucosamine also alleviates oxidative stress and lung inflammation by inhibiting the reactive oxygen species-sensitive inflammatory signaling ¹⁰. By contrast, the initial infection of SARS-CoV-2 can trigger, but might not directly involve massive inflammatory responses, and therefore glucosamine use does not alter the susceptibility to COVID-19 positivity.

4.3 Strengths and limitations of this study

The major strength of our study is the novelty of our findings. In addition, the use of

large-scale longitudinal data from the UK Biobank limits the information bias. With adjusting

for a variety of covariates, and verification by both traditional logistic regression and

propensity-score matching designs, the robustness of our findings is strengthened.

Several limitations also exist in our study. Lack of information referring to the dose and

duration of glucosamine use in the UK Biobank limits the assessment of potential causal

relationship. Information on glucosamine supplements is based on self-reported data, which

could not be verified by other sources based on the design of UK Biobank. Although a wide

range of covariates have been adjusted in our study, the results might still suffer from residual

confounding, and it is difficult to fully eliminate the effects of healthier lifestyles possessed by

glutamine users. Consequently, our findings should be carefully interpreted, while randomized

controlled trials could be conducted to further confirm their association.

5. Conclusions

Habitual glucosamine use is associated with reduced risks of hospital admission and death

with COVID-19. Further well-designed randomized-controlled trials are warranted to further

confirm its benefits.

Conflict of interest statement

The authors declared no conflict of interest.

Acknowledgement

The authors thank the UK Biobank for the access of data, and this research has been

conducted under Application Number 83339.

Funding

This work is supported by the National Natural Science Foundation of China (82171698,

82170561, 81300279, 81741067), the Program for High-level Foreign Expert Introduction of

China (G2022030047L), the Natural Science Foundation for Distinguished Young Scholars of

Guangdong Province (2021B1515020003), the Guangdong Basic and Applied Basic

Research Foundation (2022A1515012081), the Climbing Program of Introduced Talents and

High-level Hospital Construction Project of Guangdong Provincial People's Hospital

(DFJH201803, KJ012019099, KJ012021143, KY012021183), and in part by VA Clinical Merit

and ASGE clinical research funds (FWL).

Author Contributions

MJM, YJW, RJZ, and DLL contributed equally to this work. HC, WHS, QC, and FWL are

senior and corresponding authors who also contributed equally to this study. MJM, YJW, and

RJZ contributed to data extraction, data analyses, and manuscript drafting. DLL contributed to

data interpretation and manuscript drafting. RJ, HHW, ZWZ, QY, and JWL contributed to

manuscript drafting. HC, WHS, QC, and FWL contributed to study design, data interpretation,

and final approval of the manuscript. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

References

- Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet 2022;399(10334):1513-36. doi: 10.1016/s0140-6736(21)02796-3 [published Online First: 2022/03/14]
- 2. Hu B, Huang S, Yin L. The cytokine storm and COVID-19. *Journal of medical virology* 2021;93(1):250-56.
- 3. Hojyo S, Uchida M, Tanaka K, et al. How COVID-19 induces cytokine storm with high mortality. *Inflammation and regeneration* 2020;40(1):1-7.
- Abate SM, Checkol YA, Mantefardo B. Global prevalence and determinants of mortality among patients with COVID-19: A systematic review and meta-analysis. *Annals of medicine and surgery* 2021;64:102204.
- Arden NK, Perry TA, Bannuru RR, et al. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. *Nat Rev Rheumatol* 2021;17(1):59-66. doi: 10.1038/s41584-020-00523-9 [published Online First: 2020/10/30]
- Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 2008(12):1-23.
 [published Online First: 2009/04/14]
- 7. Chan PS, Caron JP, Rosa GJ, et al. Glucosamine and chondroitin sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin E(2) in articular cartilage explants. *Osteoarthritis Cartilage* 2005;13(5):387-94. doi: 10.1016/j.joca.2005.01.003 [published Online First: 2005/05/11]
- Aulak KS, Barnes JW, Tian L, et al. Specific O-GlcNAc modification at Ser-615 modulates eNOS function. Redox Biol 2020;36:101625. doi: 10.1016/j.redox.2020.101625 [published Online First: 2020/08/31]
- Hwang SY, Shin JH, Hwang JS, et al. Glucosamine exerts a neuroprotective effect via suppression of inflammation in rat brain ischemia/reperfusion injury. Glia 2010;58(15):1881-92. doi: 10.1002/glia.21058 [published Online First: 2010/08/26]
- 10. Wu YL, Lin AH, Chen CH, et al. Glucosamine attenuates cigarette smoke-induced lung

- inflammation by inhibiting ROS-sensitive inflammatory signaling. *Free Radic Biol Med* 2014;69:208-18. doi: 10.1016/j.freeradbiomed.2014.01.026 [published Online First: 2014/02/04]
- 11. Largo R, Martínez-Calatrava MJ, Sánchez-Pernaute O, et al. Effect of a high dose of glucosamine on systemic and tissue inflammation in an experimental model of atherosclerosis aggravated by chronic arthritis. Am J Physiol Heart Circ Physiol 2009;297(1):H268-76. doi: 10.1152/ajpheart.00142.2009 [published Online First: 2009/05/05]
- 12. Li ZH, Gao X, Chung VC, et al. Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study. *Ann Rheum Dis* 2020;79(6):829-36. doi: 10.1136/annrheumdis-2020-217176 [published Online First: 2020/04/08]
- 13. Ma H, Li X, Zhou T, et al. Glucosamine Use, Inflammation, and Genetic Susceptibility, and Incidence of Type 2 Diabetes: A Prospective Study in UK Biobank. *Diabetes Care* 2020;43(4):719-25. doi: 10.2337/dc19-1836 [published Online First: 2020/01/29]
- 14. Li G, Zhang X, Liu Y, et al. Relationship between glucosamine use and the risk of lung cancer: data from a nationwide prospective cohort study. *Eur Respir J* 2022;59(3) doi: 10.1183/13993003.01399-2021 [published Online First: 2021/07/31]
- Ma H, Li X, Sun D, et al. Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank. *Bmj* 2019;365:l1628. doi: 10.1136/bmj.l1628 [published Online First: 2019/05/16]
- Bell GA, Kantor ED, Lampe JW, et al. Use of glucosamine and chondroitin in relation to mortality. Eur J Epidemiol 2012;27(8):593-603. doi: 10.1007/s10654-012-9714-6 [published Online First: 2012/07/26]
- Pocobelli G, Kristal AR, Patterson RE, et al. Total mortality risk in relation to use of less-common dietary supplements. Am J Clin Nutr 2010;91(6):1791-800. doi: 10.3945/ajcn.2009.28639 [published Online First: 2010/04/23]
- 18. Hui L, Nelson E, Lin S, et al. The role of vitamin C in pneumonia and COVID-19 infection in adults with European ancestry: a Mendelian randomisation study. *European journal of clinical nutrition* 2022;76(4):588-91.

- 19. Hastie CE, Pell JP, Sattar N. Vitamin D and COVID-19 infection and mortality in UK Biobank. *European Journal of Nutrition* 2021;60(1):545-48.
- 20. Topless R, Green R, Morgan SL, et al. Folic acid and methotrexate use and their association with COVID-19 diagnosis and mortality: a case-control analysis from the UK Biobank. *BMJ Open* 2022;12(8):e062945. doi: 10.1136/bmjopen-2022-062945 [published Online First: 2022/08/25]
- 21. Felson DT. Concerns about report suggesting glucosamine and chondroitin protect against cartilage loss. *Annals of the Rheumatic Diseases* 2015;74(8):e38-e38.
- 22. Tay MZ, Poh CM, Rénia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. *Nature Reviews Immunology* 2020;20(6):363-74.
- 23. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. *The Lancet Respiratory Medicine* 2020;8(6):e46-e47.
- 24. Zhang Q, Bastard P, Bolze A, et al. Life-threatening COVID-19: defective interferons unleash excessive inflammation. *Med* 2020;1(1):14-20.
- 25. Silva JF, Olivon VC, Mestriner FLA, et al. Acute increase in O-GlcNAc improves survival in mice with LPS-induced systemic inflammatory response syndrome. Frontiers in physiology 2020;10:1614.

Figure Legends

Figure 1. Flow chart of eligible participants selection.

Figure 2. Stratified analysis of glucosamine regular users and risk of SARS-CoV-2

infection and COVID-19-related outcome. Effect estimates were based on age, sex, body

mass index (BMI), deprivation index, household income, smoking status, alcohol consumption,

education, antihypertensive drug, non-aspirin NSAID, hypercholesterolemia, type 2 diabetes,

hypertension, arthritis, using the fully adjusted model. CI: confidence interval; HR hazard ratio

P:P value for interaction.

Supplementary Figure 1. Directed acyclic graph (DAG) for evaluation of covariates in

the Cox proportional hazard analysis model. Nodes and arrows respectively represent

variables and causal associations. The exposure (Glucosamine) is denoted by a red node,

and the outcome (SARS-CoV-2 infection or COVID-19-related outcomes) is labeled by a blue


node. The proposed causal associations were based on existed literature and expert study.

BMI: body mass index; NSAID: Non-steroidal Anti-inflammatory Drugs.

Figure 1 n=502,413 Total UK Biobank participants n=194,385 **Excluded** Any missing complete glucosamine-covariate data n=308,028 Participants with complete baseline data n=181,510 **Excluded** 152,603 Any missing COVID-19 data **28,907** Any died before 31 January 2020 n=126,518 Total included in analysis of SARS-CoV-2 infection or n=160 COVID-19-related outcomes **Excluded** Any died from the virus without being hospitalized n=126,358 n=126,518 n=126,518

Participants included in analysis of SARS-CoV-2 infection

Participants included in analysis of COVID-19 mortality Participants included in analysis of COVID-19 hospital admission



Characteristics	Glucosamine	Glucosamine	Overall	
	non-user	user		
Number of participants, n(%)	106,400 (84.1)	20,118 (15.9)	126,518 (100%)	
Age, mean(SD), years	54.47 (7.69)	54.47 (7.69)	55.06 (7.67)	
Sex				
Female, n(%)	61,239 (57.6)	13,128 (65.3)	74,367 (58.8)	
Male, n(%)	45,161 (42.4)	6,990 (34.7)	52,151 (41.2)	
Ethnicity				
White, n(%)	102,593 (96.4)	19,550 (97.2)	122,143 (96.5)	
Other, n(%)	3,807 (3.6)	568 (2.8)	4,375 (3.5)	
Deprivation index, mean(SD)	-1.75 (2.82)	-2.06 (2.62)	-1.80 (2.79)	
Household income (£)				
<18 000, n(%)	11,345 (10.7)	2,350 (11.7)	13,695 (10.8)	
18 000-30 999, n(%)	20,713 (19.5)	4,736 (23.5)	25,449 (20.1)	
31 000-51 999, n(%)	28,924 (27.2)	5,445 (27.1)	34,369 (27.2)	
52 000-100 000, n(%)	27,386 (25.7)	4,349 (21.6)	31,735 (25.1)	
>100 000, n(%)	8,077 (7.6)	1,113 (5.5)	9,190 (7.3)	
Missing data	9,955 (9.4)	2,125 (10.6)	12,080 (9.5)	
BMI, mean(SD), kg/m2	26.78 (4.62)	26.69 (4.42)	26.77 (4.58)	
Alcohol consumption				
Daily or almost daily, n(%)	23,509 (22.1)	4,931 (24.5)	28,440 (22.5)	
Three or four times a week, n(%)	27,939 (26.3)	5,585 (27.8)	33,524 (26.5)	
Once or twice a week, n(%)	27,461 (25.8)	4,900 (24.4)	32,361 (25.6)	
One to three times a month, n(%)	11,745 (11.0)	2,027 (10.1)	13,772 (10.9)	
Special occasions only , n(%)	9,779 (9.2)	1,663 (8.3)	11,442 (9.0)	
Never, n(%)	5,967 (5.6)	1,012 (5.0)	6,979 (5.5)	
Smoking status				
Never smoker, n(%)	62,653 (58.9)	11,347 (56.4)	74,000 (58.5)	
Previous smoker, n(%)	35,574 (33.4)	7,740 (38.5)	43,314 (34.2)	
Current smoker, n(%)	8,173 (7.7)	1,031 (5.1)	9,204 (7.3)	
Education				
College or university degree	58,318 (54.8)	11,399 (56.7)	69,717 (55.1)	
Non-College or university degree	48,082 (45.2)	8,719 (43.3)		
Fresh fruit (tablespoons/day)				
<2, n(%)	34,715 (32.6)	4,504 (22.4)	39,219 (31.0)	
2-3.9, n(%)	54,723 (51.4)	11,326 (56.3)	66,049 (52.2)	
≥3.9, n(%)	16,962 (15.9)	4,288 (21.3)	21,250 (16.8)	
Raw vegetable (tablespoons/day)				
<2, n(%)	44,541 (41.9)	7,197 (35.8)	51,738 (40.9)	
2-3.9, n(%)	43,782 (41.1)	8,615 (42.8)	52,397 (41.4)	
≥3.9, n(%)	18,077 (17.0)	4,306 (21.4)	22,383 (17.7)	
Supplement or co-medication use:				
Vitamin supplementation, n(%)				

which was not certified by peer review) is t	the author/funder, who has grar ghts reserved. No reuse allowe	nted medRxiv a license to d	isplay the preprint in perpe	
Use, n(%)	28,541 (26.8)	12,611 (62.7)	41,152 (32.5)	
Non-use, n(%)	77,859 (73.2)	7,507 (37.3)	85,366 (67.5)	
Mineral and other dietary				
supplementation, n(%)				
Use, n(%)	31,062 (29.2)	20,037 (99.6)	51,099 (40.4)	
Non-use, n(%)	75,338 (70.8)	81 (0.4)	75,419 (59.6)	
Antihypertensive drug, n(%)				
Use, n(%)	16,989 (16.0)	3,274 (16.3)	20,263 (16.0)	
Non-use, n(%)	89,411 (84.0)	16,844 (83.7)	106,255 (84.0)	
Hypolipidemic drug, n(%)				
Use, n(%)	13,514 (12.7)	2,651 (13.2)	16,165 (12.8)	
Non-use, n(%)	92,886 (87.3)	17,467 (86.8)	110,353 (87.2)	
Insulin, n(%)				
Use, n(%)	803 (0.8)	101 (0.5)	904 (0.7)	
Non-use, n(%)	105,597 (99.2)	20,017 (99.5)	125,614 (99.3)	
Aspirin, n(%)				
Use, n(%)	11,110 (10.4)	2,488 (12.4)	13,598 (10.7)	
Non-use, n(%)	95,290 (89.6)	17,630 (87.6)	112,920 (89.3)	
Non-aspirin NSAID, n(%)				
Use, n(%)	28,863 (27.1)	6,559 (32.6)	35,422 (28.0)	
Non-use, n(%)	77,537 (72.9)	13,559 (67.4)	91,096(72.0)	
Comorbidities:				
Hypertension, n(%)				
Yes, n(%)	23,736 (22.3)	5,088 (25.3)	28,824 (22.8)	
No, n(%)	82,664 (77.7)	15,030 (74.7)	97,694 (77.2)	
Type 2 diabetes, n(%)				
Yes, n(%)	5,210 (4.9)	834 (4.1)	6,044 (4.8)	
No, n(%)	101,190 (95.1)	19,284 (95.9)	120,474 (95.2)	
Hypercholesterolemia, n(%)				
Yes, n(%)	10,337 (9.7)	2,267 (11.3)	12,604 (10.0)	
No, n(%)	96,063 (90.3)	17,851 (88.7)	113,914 (90.0)	
Arthritis, n(%)				
Yes, n(%)	7,830 (7.4)	2,578 (12.8)	10,408 (8.2)	
No, n(%)	98,570 (92.6)	17,540 (87.2)	116,110 (91.8)	

BMI: body mass index; NSAID: non-steroidal anti-inflammatory drug; SD: standard deviation

Table 2. Associations of use of glucosamine with the risk of SARS-CoV-2 infection and COVID-19-related outcomes

	Case/person- years	Non-adjusted model		Age and sex-adjusted model		Fully adjusted model*	
		HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
SARS-CoV-2 infection							
Glucosamine non-user	44,768/543,655	1.00 (Reference)		1.00(Reference)		1.00(Reference)	
Glucosamine user	8,914/108,101	1.10(1.07-1.12)	<0.001	0.97(0.95-1.00)	0.020	1.02(0.99-1.05)	0.180
COVID-19 hospital admission							
Glucosamine non-user	1,856/21,689	1.00 (Reference)		1.00(Reference)		1.00(Reference)	
Glucosamine user	264/3,059	0.77(0.67-0.87)	<0.001	0.67(0.58-0.76)	<0.001	0.73(0.63-0.85)	<0.001
COVID-19 mortality							
Glucosamine non-user	476/5,586	1.00 (Reference)		1.00(Reference)		1.00(Reference)	
Glucosamine user	72/843	0.82(0.64-1.05)	0.110	0.61(0.47-0.78)	<0.001	0.74(0.56-0.98)	0.040

CI: confidence interval; HR: hazard ratio

^{*}Adjusted for age, sex, race (white European, others), Townsend Deprivation Index, average total annual household income (<£18 000, £18 000, £30 999, £31 000-£51 999, £52 000-£100 000, >£100 000, and "do not know" or missing), body mass index, smoking status (never, former, current), alcohol intake, education (with college or university degree, no college degree), fresh fruit consumption (<2.0, 2.0-3.9, or ≥3.9 tablespoons/day), raw vegetable consumption (<2.0, 2.0-3.9, or ≥3.9 tablespoons/day), vitamin supplement use (yes or no), mineral and other dietary supplement use (yes or no), antihypertensive drugs (yes or no), hypercholesterolemia (yes or no), insulin treatment (yes or no), aspirin use (yes or no), non-aspirin NSAID use (yes or no), type 2 diabetes (yes or no), hypertension (yes or no), hypercholesterolemia (yes or no), arthritis (yes or no).